Malahat Safavi

Malahat Safavi

Auto-generated profile, based on publicly available information

Malahat Safavi

Department of Food Industry Science and Engineering, Faculty of Agriculture, University of Tabriz, Tabriz, Iran

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2025 in Advanced Pharmaceutical Bulletin
Verified
Journal Article
Open access
SASoheil Abbaspour-Ravasjani
Soheil Abbaspour-Ravasjani
MZMahdi Zeinali
Mahdi Zeinali
LALeila Asadollahi
Leila Asadollahi
MSMalahat Safavi
Malahat Safavi
AMAmin Mahoutforoush
Amin Mahoutforoush
HHHamed Hamishehkar
Hamed Hamishehkar
Purpose: Colorectal cancer (CRC) is a formidable global health challenge, ranking as the third most prevalent cancer. Conventional treatments like surgery, radiation, and chemotherapy are limited by adverse effects, driving the search for more effective alternatives. Methods: This study investigates the synergistic potential of co-delivering 5-fluorouracil (5-FU) and cannabidiol (CBD) using hyaluronic acid (HA)-decorated liposomes. While 5-FU is a cornerstone of CRC treatment, CBD offers promise as an anti-tumor agent. The HA-decorated liposomes enable potential targeted drug delivery to CD44 receptors, which are overexpressed in CRC, while minimizing systemic toxicity by reducing the concentrations of anticancer drugs required. Results: The liposomal formulation displays optimal physicochemical properties (a sub-100-nm size and an appropriate negative zeta potential) and acceptable encapsulation and loading efficiencies, ensuring effective drug release. In vitro studies demonstrate that the targeted liposomes' have superior anticancer effects, inducing apoptosis (up to 59.1%), cell cycle arrest in the Sub-G1 and G0-G1 phases, reduction of cell viability to 6.98% in human colorectal adenocarcinoma (HT‐29) cells, induction of oxidative stress, and inhibition of colony formation. Additionally, HepG2 (non-CD44-expressing) cells were used as a control to evaluate CD44-targeting efficiency. Gene expression analysis by real-time PCR indicates modulation of key genes associated with cell cycle progression and apoptosis. Conclusion: This multifaceted approach presents a promising strategy for CRC therapy, but requires additional optimization and rigorous in vivo investigations to facilitate successful clinical translation. In particular, optimization of drug-release kinetics and thorough in vivo validation are essential to advance this platform toward clinical application.

1 July 2026 in Advanced Pharmaceutical Bulletin
Verified
Journal Article
Closed access
SASoheil Abbaspour-Ravasjani
Soheil Abbaspour-Ravasjani
RSRahim Shahvalizadeh
Rahim Shahvalizadeh
MSMalahat Safavi
Malahat Safavi
MNMina A Frashteh Nour
Mina A Frashteh Nour
MTMahdi Talebi
Mahdi Talebi
HHHamed Hamishehkar
Hamed Hamishehkar
Background: Vitamin D3 (Vit D3) possesses pleiotropic anticancer activity; however, its clinical application is limited by poor bioavailability and nonselective cellular uptake. This study aimed to develop folate (FA)-targeted, pH-sensitive liposomes for enhanced delivery of Vit D3 to breast cancer cells and to evaluate their effects on the VDR/EZH2/STAT3 signaling axis. Methods: Vit D3-loaded pH-sensitive liposomes were formulated and characterized for particle size, zeta potential, encapsulation efficiency, stability, and pH-responsive release. Cellular uptake, cytotoxicity, clonogenicity, apoptosis, reactive oxygen species (ROS) generation, autophagy, cell-cycle distribution, RT-qPCR, and Western blotting were evaluated in MCF-7 cells. Results: The optimized formulations exhibited nanoscale particle size, high encapsulation efficiency, physicochemical stability, and enhanced acidic pH-triggered release. FA-targeted liposomes significantly increased cellular uptake and cytotoxicity compared with free Vit D3 and non-targeted liposomes, with IC50 values of 15, 11, and 7.2 IU · mL-1, respectively. Vit D3-PEG/lipo-FA induced a 3.2-fold upregulation of VDR expression while suppressing EZH2 and STAT3 expression by 60% and 50%, respectively. In addition, treatment increased Caspase-3, LC3B, and NOX4 expression, promoted apoptosis and ROS generation, altered cell-cycle progression, and markedly reduced clonogenic survival. Western blot analysis confirmed these molecular alterations at the protein level. Conclusion: FA-targeted pH-sensitive liposomal delivery significantly enhances the anticancer efficacy of Vit D3 in MCF-7 cells by modulating the VDR/EZH2/STAT3 axis and activating apoptosis-, autophagy-, and ROS-associated pathways, highlighting its potential as a targeted nanotherapeutic strategy for breast cancer treatment.